Advertisement

Topics

bluebird bio Announces Publication of Case Study on First Patient with Severe Sickle Cell Disease Treated with Gene Therapy in The New England Journal of Medicine

17:00 EST 1 Mar 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
– Patient treated with LentiGlobinTM drug product demonstrates high levels (~50% of total hemoglobin) of anti-sickling hemoglobin (HbAT87Q) 15 months after treatment – bluebird bio, Inc. (Nasdaq: ...

Other Sources for this Article

Investors:
bluebird bio, Inc.
Manisha Pai, 617-245-2107
mpai@bluebirdbio.com
or
Media:
bluebird bio, Inc.
Elizabeth Pingpank, 617-914-8736
epingpank@bluebirdbio.com
or
Pure Communications, Inc.
Dan Budwick, 973-271-6085
or
AP-HP:
Anne-Cécile Bard and Marine Leroy, +33 (0)1 40 27 37 22
service.presse@aphp.fr
or
Imagine Institute, Paris, France:
Béatrice Parrinello-Froment, +33 (0)6 63 72 16 06
beatriceparrinello@bpfconseil.com
or
Pauline Rodrigue-Moriconi, +33 (0)6 77 23 71 19
pauline.rodrigue@institutimagine.org

NEXT ARTICLE

More From BioPortfolio on "bluebird bio Announces Publication of Case Study on First Patient with Severe Sickle Cell Disease Treated with Gene Therapy in The New England Journal of Medicine"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Blood
Blood is a specialized bodily fluid that delivers necessary substances to the body's cells (in animals) – such as nutrients and oxygen – and transports waste products away from those same cells.  In vertebrates, it is composed of blo...